Ionis Pharmaceuticals, Inc. Option Agreement (Nonstatutory Stock Option)Option Agreement • February 22nd, 2023 • Ionis Pharmaceuticals Inc • Pharmaceutical preparations
Pursuant to your Stock Option Grant Notice (“Grant Notice”) and this Option Agreement, Ionis Pharmaceuticals, Inc. (the “Company”) has granted you an option under its 2011 Equity Incentive Plan (the “Plan”) to purchase the number of shares of the Company’s Common Stock indicated in your Grant Notice at the exercise price indicated in your Grant Notice. Capitalized terms not explicitly defined in this Option Agreement but defined in the Plan shall have the same definitions as in the Plan.
PURCHASE AND SALE AGREEMENTPurchase and Sale Agreement • February 22nd, 2023 • Ionis Pharmaceuticals Inc • Pharmaceutical preparations • California
This PURCHASE AND SALE AGREEMENT (as the same may be amended, modified, or supplemented from time to time in accordance with the terms hereof, this “Agreement”), dated effective for all purposes as of October 20, 2022, is by and between IONIS GAZELLE, LLC, a Delaware limited liability company (“Seller”), and 2850 2855 & 2859 GAZELLE OWNER (DE) LLC, a Delaware limited liability company (together with its successors and/or assigns, collectively, “Buyer”).
DEFEASANCE PLEDGE AND SECURITY AGREEMENTDefeasance Pledge and Security Agreement • February 22nd, 2023 • Ionis Pharmaceuticals Inc • Pharmaceutical preparations
DEFEASANCE ASSIGNMENT, ASSUMPTION AND RELEASE AGREEMENTDefeasance Assignment, Assumption and Release Agreement • February 22nd, 2023 • Ionis Pharmaceuticals Inc • Pharmaceutical preparations
THIS DEFEASANCE ASSIGNMENT, ASSUMPTION AND RELEASE AGREEMENT (this “Agreement”) dated as of October 20, 2022 is made by and among IONIS GAZELLE, LLC, a Delaware limited liability company (“Original Borrower”), DHC UBSCM 17 C3 SUCCESSOR BORROWER-R, LLC, a Delaware limited liability company (“Successor Borrower”), WELLS FARGO BANK, NATIONAL ASSOCIATION, AS TRUSTEE FOR THE BENEFIT OF THE REGISTERED HOLDERS OF UBS COMMERCIAL MORTGAGE TRUST 2017-C3, COMMERCIAL MORTGAGE PASS-THROUGH CERTIFICATES, SERIES 2017-C3, as secured party (together with its successors and assigns, “Lender”), MIDLAND LOAN SERVICES, a division of PNC Bank, National Association (“Servicer”), on behalf of said Trustee under the Pooling and Servicing Agreement (as hereinafter defined), and, for the sole purpose of acknowledging the transactions effected by this Agreement, U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION, a national banking association, as Securities Intermediary and Custodian (together with its successors and
LEASE AGREEMENT DATEDLease Agreement • February 22nd, 2023 • Ionis Pharmaceuticals Inc • Pharmaceutical preparations • California
This Lease Agreement (this “Lease”), dated ____________, 2022 (the “Effective Date”), is made between 2850 2855 & 2859 Gazelle Owner (DE) LLC, a Delaware limited liability company (“Landlord”), and Ionis Pharmaceuticals, Inc., a Delaware corporation (“Tenant”).
DEFEASANCE ACCOUNT AGREEMENTDefeasance Account Agreement • February 22nd, 2023 • Ionis Pharmaceuticals Inc • Pharmaceutical preparations
THIS DEFEASANCE ACCOUNT AGREEMENT (this “Agreement”) is entered into as of October 20, 2022 by and among IONIS GAZELLE, LLC, a Delaware limited liability company (“Original Borrower”), U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION, a national banking association, as Securities Intermediary and Custodian (together with its permitted successors and assigns, “Intermediary”), U.S. BANK NATIONAL ASSOCIATION, a national banking association (“Account Bank”), WELLS FARGO BANK, NATIONAL ASSOCIATION, AS TRUSTEE FOR THE BENEFIT OF THE REGISTERED HOLDERS OF UBS COMMERCIAL MORTGAGE TRUST 2017-C3, COMMERCIAL MORTGAGE PASS-THROUGH CERTIFICATES, SERIES 2017-C3, as secured party (together with its successors and assigns, “Lender”), and MIDLAND LOAN SERVICES, a division of PNC Bank, National Association (“Servicer”), as Master Servicer on behalf of said Trustee under the Pooling and Servicing Agreement (as hereinafter defined).
Ionis Pharmaceuticals, Inc. Restricted Stock Unit AgreementRestricted Stock Unit Agreement • February 22nd, 2023 • Ionis Pharmaceuticals Inc • Pharmaceutical preparations • California
Pursuant to the Restricted Stock Unit Grant Notice (“Grant Notice”) and this Restricted Stock Unit Agreement and in consideration of your services, Ionis Pharmaceuticals, Inc. (the “Company”) has awarded you a Restricted Stock Unit Award (the “Award”) under its 2011 Equity Incentive Plan (the “Plan”). Your Award is granted to you effective as of the Date of Grant set forth in the Grant Notice for this Award. This Restricted Stock Unit Award Agreement shall be deemed to be agreed to by the Company and you upon the earlier of (i) signing (or electronic acceptance) by you of the Restricted Stock Unit Grant Notice to which it is attached, and (ii) your receipt of shares of Common Stock under this Restricted Stock Unit Agreement. Capitalized terms not explicitly defined in this Restricted Stock Unit Agreement shall have the same meanings given to them in the Plan or the Grant Notice, as applicable. In the event of any conflict between the terms in this Restricted Stock Unit Agreement and th
COLLABORATION AND LICENSE AGREEMENT BETWEENCollaboration and License Agreement • February 22nd, 2023 • Ionis Pharmaceuticals Inc • Pharmaceutical preparations • New York
This COLLABORATION AND LICENSE AGREEMENT (this “Agreement”) is entered into as of November 10, 2022 (the “Effective Date”), by and between Ionis Pharmaceuticals, Inc., a Delaware corporation, having its principal place of business at 2855 Gazelle Court, Carlsbad, CA 92010 (“Ionis”), and Metagenomi, Inc., a Delaware corporation, having its principal place of business at 1545 Park Avenue, Emeryville, CA 94608 (“Metagenomi”). Metagenomi and Ionis are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”
Royalty Purchase Agreement By and Between Ionis Pharmaceuticals, Inc. and Akcea Therapeutics, Inc. (for the limited purposes set forth herein) and Royalty Pharma Investments 2019 ICAV Dated as of January 9, 2023Royalty Purchase Agreement • February 22nd, 2023 • Ionis Pharmaceuticals Inc • Pharmaceutical preparations • New York
This ROYALTY PURCHASE AGREEMENT, dated as of January 9, 2023 (this “Agreement”), is made and entered into by and between Ionis Pharmaceuticals, Inc., a Delaware corporation (the “Seller”) and, solely for the limited purposes set forth in Sections 2.1(a), 2.2, 2.3, 3.2, 3.4, 5.10(c) (the last sentence only), 5.14(b)(i), 5.14(b)(iii) and 9.3 hereunder, Akcea Therapeutics, Inc., a Delaware corporation (“Akcea”), on the one hand, and Royalty Pharma Investments 2019 ICAV, an Irish collective asset-management vehicle (the “Buyer”), on the other hand. Unless otherwise defined in this Agreement, capitalized terms have the meanings ascribed to them in Section 1 below.
LEASE AGREEMENT by and between SUDBERRY DEVELOPMENT, INC., a California corporation, as Landlord and IONIS PHARMACEUTICALS, INC., a Delaware corporation, as Tenant Dated as of October 6, 2022Lease Agreement • February 22nd, 2023 • Ionis Pharmaceuticals Inc • Pharmaceutical preparations • California
THIS LEASE AGREEMENT (this “Lease”) is made as of October 6, 2022 (the “Effective Date”), by and between SUDBERRY DEVELOPMENT, INC., a California corporation (the “Landlord”), and IONIS PHARMACEUTICALS, INC., a Delaware corporation (the “Tenant”).
